Relationship of Urine Dopamine with Phosphorus Homeostasis in Humans: The Heart and Soul Study

Nisha Bansal\textsuperscript{a} Chi-yuan Hsu\textsuperscript{a} Mary Whooley\textsuperscript{a–c} Anders H. Berg\textsuperscript{d} Joachim H. Ix\textsuperscript{e–g}

Departments of \textsuperscript{a}Medicine and \textsuperscript{b}Epidemiology and Biostatistics, University of California, San Francisco, and \textsuperscript{c}San Francisco Veterans Affairs Medical Center, San Francisco, Calif., \textsuperscript{d}Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Mass., \textsuperscript{e}Nephrology Section, Veterans Affairs San Diego Healthcare System, \textsuperscript{f}Department of Medicine, Division of Nephrology, and \textsuperscript{g}Department of Family and Preventative Medicine, Division of Preventative Medicine, University of California, San Diego, San Diego, Calif., USA

Key Words
Urine dopamine · Phosphorus · Kidney · Proximal tubule

Abstract

Background: Urine dopamine (DA) is produced in the proximal tubule and has been found to increase in response to dietary phosphorus intake, and to contribute to greater urinary phosphorus excretion in animal models. Whether urine DA is associated with phosphorus homeostasis in humans is uncertain. Methods: This was a cross-sectional study of 884 outpatients. DA was measured from 24-hour urine collections. We examined cross-sectional associations between urine DA and serum phosphorus, 24-hour urine phosphorus (as an indicator of dietary phosphorus absorption), fractional excretion of phosphorus (FEphos), fibroblast growth factor (FGF)-23, and parathyroid hormone (PTH). Models were adjusted for age, sex, race, eGFR, albuminuria, hypertension, heart failure, tobacco use, body mass index, and diuretic use. Results: Mean age was 66.6 ± 11 years and mean eGFR was 71 ± 21.3 ml/min/1.73 m\textsuperscript{2}. The mean urine DA was 193 ± 86 μg/day, mean serum phosphorus was 3.6 ± 0.6 mg/dl, mean daily urine phosphorus excretion was 671 ± 312 mg/day, and mean FEphos was 17 ± 9%. In adjusted models, each standard deviation higher DA was associated with 78.4 mg/day higher urine phosphorus and 0.9% lower FEphos (p < 0.05 for both). There was no statistically significant association between urine DA, serum phosphorus, FGF-23 or PTH in adjusted models. Conclusions: Higher dietary phosphorus absorption is associated with higher urine DA in humans, consistent with animal models. However, higher urine DA is not associated with FGF-23 or PTH, suggesting that known mechanisms of renal tubular handling of phosphorus may not be involved in the renal dopamine-phosphorus regulatory pathway in humans.

Introduction

Higher serum phosphorus concentrations have been linked to arterial calcification in the general population and in patients with chronic kidney disease (CKD), even at phosphorus concentrations within the normal laboratory reference range [1–3]. In vitro studies have suggested that higher phosphorus can induce vascular smooth
muscle cells to transform into osteoblast-like cells and to deposit calcium and phosphorus in the extracellular matrix, leading to arterial calcification [4]. Collectively, these findings have suggested that higher phosphorus levels may represent a novel vascular toxin, and have led to new interest in factors that may influence serum phosphorus levels in the general population.

The kidney plays an important role in phosphorus regulation. In response to the ingestion of phosphorus, there is a rapid increase in the urinary excretion of phosphorus [5]. Yet, mechanisms through which the kidney senses and responds to higher phosphorus remain incompletely understood. Animal studies have suggested that renal proximal tubule cells can sense a change in phosphorus concentration and in response, there is endogenous production of dopamine in the proximal tubule [6–8]. In addition, increases in urine dopamine may contribute to urine phosphorus excretion. In a study in rats fed a high-phosphorus diet, urine phosphorus and urine dopamine excretion were both increased, while plasma dopamine was unchanged [9]. Another study of rats fed a high-phosphorus diet found that key enzymes involved in the activation of renal dopamine receptors were activated, which inhibited renal reabsorption of phosphorus [10]. Others have demonstrated that in rats fed a low-phosphorus diet, the fractional excretion of phosphate was greater in rats infused with parathyroid hormone (PTH) plus dopamine than in those infused with PTH alone [11].

To our knowledge, no previous study has examined the relationship of urine dopamine with phosphorus homeostasis in humans. In the present study, we test the hypothesis that urine dopamine excreted in 24 h is associated with phosphorus regulation, as measured by serum phosphorus, 24-hour urine phosphorus excretion (a marker of dietary phosphorus absorption), fractional excretion of phosphorus (FEphos; reflecting renal reabsorption of phosphorus), fibroblast growth factor (FGF)-23, and PTH, in adults with stable coronary heart disease (CHD) and a spectrum of kidney function ranging from normal to moderate CKD.

**Subjects and Methods**

**Study Design and Participants**

The Heart and Soul Study is an observational study designed to investigate the influence of psychosocial factors on the progression of CHD. Methods have been described previously [12]. Briefly, participants were recruited from outpatient clinics in the San Francisco Bay area if they met one of the following inclusion criteria: history of myocardial infarction, angiographic evidence of >50% stenosis in ≥1 coronary vessels, evidence of exercise-induced ischemia by treadmill or nuclear testing, history of coronary revascularization, or documented diagnosis of CHD by an internist or cardiologist. Participants were excluded if they were not able to walk one block, had experienced myocardial infarction within the past 6 months, or were likely to move out of the area within 3 years. The study protocol was approved by the Institutional Review Boards of participating institutions, and all participants provided written informed consent. Between September 2000 and December 2002, 1,024 participants enrolled and underwent a day-long baseline study appointment that included a medical history, physical examination, and comprehensive health status questionnaire. Outpatient 24-hour timed urine collections and fasting (12-hour) morning venous blood samples were obtained at baseline. We excluded 67 participants with missing timed urine collections and another 73 due to missing baseline covariate data, providing a final analytic sample of 884 (86%) participants for this analysis.

**Measurements**

**Urine Dopamine**

Details of the protocol for 24-hour urine collections have been described previously [13]. Briefly, participants received detailed instructions on accurate urine collection and specimen refrigeration. Subjects were asked to void at the end of their study appointment and to begin the collection from that point forward. Research personnel arrived at the patients’ home 24 h after the timed collection was initiated to avoid overcollection or undercollection. If participants reported missing any urine or if collections were <1 or >3 liter, collections were repeated. If the subjects were unable to collect all urine for any reason or had urinary incontinence, their samples were deemed inadequate, and no urinary dopamine data were recorded for these subjects.

Urinary dopamine levels were measured with gas chromatography-mass spectrometry at the Associated Regional and University Pathologists laboratories, with headquarters in Salt Lake City [14]. The normal reference range for the dopamine assays is 60–440 µg/day. Because the detection limit was 1.0 µg/dl, catecholamine levels for the participants whose excretion level was below this detection limit were coded as 1.0 µg/dl [15]. To ensure adequate sampling, we measured urinary creatinine levels in parallel and included only the participants who had a urinary creatinine value within the normal range (0.8–2.1 g/day) [15].

**Markers of Phosphorus Homeostasis**

We evaluated serum phosphorus concentrations, 24-hour urine phosphorus excretion, and the urinary FEphos as outcomes of interest in this study. Serum phosphorus was measured using fasting morning blood specimens collected at the study visit using a Vitros 950iRC (Ortho Clinical Diagnostics, www.orthoclinical.com) with a measurement range of 0.3–13 mg/dl and a coefficient of variation of 3.5%, as previously described [16].

Urine phosphorus was measured from 24-hour timed urine collections [13]. Urine was mixed thoroughly and 5-ml aliquots were stored at −80°C. Specimens were thawed and treated with 1 mol/l of hydrochloric acid, and urine phosphorus was measured using a Cobas 6000 analyzer (Roche Diagnostics, www.roche.com) [16]. The lower limit of detection was 3.4 mg/dl, and the coefficient of variation was 1.4–1.7% [16]. To calculate urine phosphorus excretion in 24 h, the urine phosphorus concentra-
Urine Dopamine and Phosphorus Homeostasis

Results

Among the 884 study participants, the mean age was 67 ± 11 years, 18% were women, and the mean eGFRcys was 71 ± 21 ml/min/1.73 m². The mean urine dopamine was 193 ± 86 µg/day, serum phosphorus was 3.6 ± 0.6 mg/dl, daily urine phosphorus excretion was 671 ± 312 mg/dl, FEphos was 17 ± 9%, median FGF-23 was 42.9 (IQR 28.1–70.8) RU/ml, and mean PTH was 60 ± 34 pg/ml. Baseline characteristics of the study population by urine dopamine quartiles are shown in Table 1. Those with higher daily urine dopamine excretion were younger and less likely to be white, had higher eGFR, less albuminuria, and higher BMI. They were more likely to smoke and less likely to have heart failure or to use diuretics or ACE inhibitors. Plasma dopamine and serum phosphorus levels did not differ significantly across urine dopamine quartile. Participants with higher urine dopamine had lower serum creatinine, higher 24-hour urine creatinine and lower FEphos. Participants with higher urine dopamine also had higher 24-hour urine phosphorus excretions. FGF-23 was higher and PTH was lower among participants with higher urine dopamine.

Table 2 shows a correlation matrix of daily urine dopamine excretion, serum phosphorus, daily urine phosphorus excretion, FEphos, eGFRcys, FGF-23, and PTH. Direct correlations of moderate strength were observed between urine dopamine and eGFRcys, urine phosphorus and urine dopamine, and urine phosphorus and FEphos, whereas moderate inverse correlations were observed between eGFRcys and FEphos, eGFRcys and FGF-23, and eGFRcys and PTH.

We did not observe a statistically significant association between 24-hour urine dopamine excretion with serum phosphorus concentrations; results were similar in both unadjusted and adjusted models (Table 3). In contrast, we observed a statistically significant direct association of daily urine dopamine excretion with daily...
Table 1. Baseline characteristics of study population by urine dopamine quartiles (n = 884)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>I (&lt;133 μg/day) (n = 223)</th>
<th>II (133–185 μg/day) (n = 219)</th>
<th>III (186–241 μg/day) (n = 221)</th>
<th>IV (≥242 μg/day) (n = 221)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>72 ± 11</td>
<td>68.1 ± 10.2</td>
<td>66 ± 9.5</td>
<td>60.3 ± 9.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Female, %</td>
<td>18</td>
<td>27</td>
<td>14</td>
<td>14</td>
<td>0.001</td>
</tr>
<tr>
<td>Race, %</td>
<td>0.002</td>
<td>0.002</td>
<td>0.002</td>
<td>0.002</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>63</td>
<td>62</td>
<td>65</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>12</td>
<td>11</td>
<td>15</td>
<td>24</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>26</td>
<td>27</td>
<td>20</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Diabetes, %</td>
<td>28</td>
<td>27</td>
<td>23</td>
<td>28</td>
<td>0.6</td>
</tr>
<tr>
<td>Hypertension, %</td>
<td>74</td>
<td>75</td>
<td>64</td>
<td>72</td>
<td>0.05</td>
</tr>
<tr>
<td>Prior myocardial infarction, %</td>
<td>54</td>
<td>54</td>
<td>52</td>
<td>57</td>
<td>0.7</td>
</tr>
<tr>
<td>Prior congestive heart failure, %</td>
<td>23</td>
<td>18</td>
<td>14</td>
<td>15</td>
<td>0.04</td>
</tr>
<tr>
<td>Current tobacco use, %</td>
<td>14</td>
<td>20</td>
<td>16</td>
<td>29</td>
<td>0.001</td>
</tr>
<tr>
<td>Diuretic use, %</td>
<td>40</td>
<td>31</td>
<td>28</td>
<td>22</td>
<td>0.001</td>
</tr>
<tr>
<td>Antidepressant use, %</td>
<td>22</td>
<td>17</td>
<td>15</td>
<td>19</td>
<td>0.4</td>
</tr>
<tr>
<td>β-blocker use, %</td>
<td>61</td>
<td>61</td>
<td>58</td>
<td>52</td>
<td>0.1</td>
</tr>
<tr>
<td>ACE inhibitor/ARB use, %</td>
<td>61</td>
<td>48</td>
<td>51</td>
<td>49</td>
<td>0.04</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>135 (120, 148)</td>
<td>130 (120, 144)</td>
<td>130 (120, 144)</td>
<td>130 (120, 140)</td>
<td>0.2</td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
<td>74 ± 11</td>
<td>74 ± 12</td>
<td>75 ± 11</td>
<td>75 ± 11</td>
<td>0.4</td>
</tr>
<tr>
<td>BMI</td>
<td>26.2 (23.9, 28.9)</td>
<td>27.6 (24.7, 30.5)</td>
<td>28.3 (25.5, 30.9)</td>
<td>29.6 (26, 33.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CRP, mg/l</td>
<td>2 (1, 5)</td>
<td>2 (1, 5)</td>
<td>3 (1, 5)</td>
<td>2 (1, 5)</td>
<td>0.6</td>
</tr>
<tr>
<td>eGFR, ml/min/1.73 m²</td>
<td>56 (44, 70)</td>
<td>68 (55, 82)</td>
<td>74 (62, 87)</td>
<td>83 (72, 96)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Serum creatinine, mg/dl</td>
<td>1.3 ± 0.6</td>
<td>1.1 ± 0.3</td>
<td>1.0 ± 0.4</td>
<td>0.9 ± 0.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>24-hour urine creatinine, mg/day</td>
<td>937 ± 313</td>
<td>1,077 ± 354</td>
<td>1,305 ± 330</td>
<td>1,476 ± 421</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Urine albumin/creatinine, mg/g</td>
<td>12.7 (7.4, 37.1)</td>
<td>8.7 (5.1, 17.5)</td>
<td>8.4 (5.0, 16.1)</td>
<td>7.1 (3.9, 12)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Plasma dopamine, pg/ml</td>
<td>15 (15, 20)</td>
<td>15 (15, 18)</td>
<td>15 (15, 18)</td>
<td>15 (15, 20)</td>
<td>0.7</td>
</tr>
<tr>
<td>Serum calcium, mg/dl</td>
<td>9.5 ± 0.5</td>
<td>9.5 ± 0.5</td>
<td>9.6 ± 0.5</td>
<td>9.6 ± 0.5</td>
<td>0.1</td>
</tr>
<tr>
<td>Serum phosphorus, mg/dl</td>
<td>3.7 ± 0.6</td>
<td>3.7 ± 0.6</td>
<td>3.6 ± 0.5</td>
<td>3.7 ± 0.6</td>
<td>0.2</td>
</tr>
<tr>
<td>24-hour urine phosphorus, mg/day</td>
<td>476 (343, 675)</td>
<td>597 (432, 772)</td>
<td>667 (496, 834)</td>
<td>847 (557, 1,044)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEphos, %</td>
<td>19 (14, 26)</td>
<td>17 (12, 22)</td>
<td>15 (11, 19)</td>
<td>14 (10, 19)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FGF-23, RU/ml</td>
<td>58.4 (36.3, 111.2)</td>
<td>44.8 (29.8, 66.7)</td>
<td>37.8 (25.1, 54.0)</td>
<td>36.2 (24.4, 55.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>PTH⁴, pg/ml</td>
<td>68 ± 46</td>
<td>61 ± 35</td>
<td>58 ± 25</td>
<td>52 ± 21</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Data are mean ± SD or median (IQR), unless otherwise indicated.

Table 2. Correlation matrix between urine dopamine, measures of phosphorus homeostasis and eGFRcys⁴

<table>
<thead>
<tr>
<th>Variables</th>
<th>Urine dopamine</th>
<th>Serum phosphorus</th>
<th>24-hour urine phosphorus</th>
<th>FEphos</th>
<th>eGFRcys</th>
<th>FGF-23</th>
<th>PTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Urine dopamine</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum phosphorus</td>
<td>0.03</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24-hour urine phosphorus</td>
<td>0.4</td>
<td>0.04</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEphos</td>
<td>−0.3</td>
<td>−0.2</td>
<td>0.4</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>eGFRcys</td>
<td>0.4</td>
<td>−0.1</td>
<td>0.2</td>
<td>−0.4</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FGF-23</td>
<td>−0.2</td>
<td>0.2</td>
<td>−0.03</td>
<td>0.2</td>
<td>−0.4</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>PTH</td>
<td>−0.2</td>
<td>−0.1</td>
<td>−0.1</td>
<td>0.3</td>
<td>−0.4</td>
<td>0.2</td>
<td>1.0</td>
</tr>
</tbody>
</table>

* All presented correlations are Pearson’s correlation coefficients.
urine phosphorus excretion. In unadjusted models, each standard deviation higher urine dopamine excretion was associated with a 113 (95% CI 93–132) mg/dl higher daily urine phosphorus excretion (p < 0.001). This association remained similar throughout the sequence of adjusted models. We also observed a statistically significant association between higher daily urine dopamine excretion and lower FEphos. Each standard deviation higher daily urine dopamine excretion was associated with approximately 1% lower FEphos in fully adjusted models. We explored associations between urine dopamine and FGF-23. In unadjusted models, higher urine dopamine was associated with lower FGF-23; however, this association was attenuated after adjustment for eGFRcys and urine albumin/creatinine. Similarly, the association between higher urine dopamine and lower PTH was statistically significant in unadjusted models and models adjusted for age, sex, and race; however, after adjustment for eGFRcys and urine albumin/creatinine, the association was rendered no longer statistically significant.

Given a direct association of urine dopamine with urine phosphorus excretion, but an inverse association with FEphos, we explored the association between urine dopamine and serum and urine creatinine. We found that each standard deviation higher urine dopamine was independently associated with 6.5 mg/dl higher serum creatinine (95% CI 3.5–9.5, p < 0.001) and 0.06 mg/dl lower serum creatinine (95% CI –0.06 to –0.04, p < 0.001) in models adjusted for age, sex, race, eGFRcys, urine albumin/creatinine, ACE/ARB use, heart failure, tobacco use, BMI, and diuretic use.

The relationships of daily urine dopamine excretion with serum phosphorus, 24-hour urine phosphorus excretion, FEphos, FGF-23, and PTH were all similar by

| Table 3. Association of urine dopamine with measures of phosphorus homeostasis (n = 884) |
|---------------------------------|----------------|----------------|----------------|----------------|----------------|
|                                 | Quartile 2     | Quartile 3     | Quartile 4     | Continuous (per SD increase) |
|                                 | range          | p value        | range          | p value        | range          | p value        |
| Serum phosphorus, mg/dl          |                |                |                |                |                |
| Unadjusted                      | 0.008 (–0.1, 0.1) | 0.9            | –0.02 (–0.1, 0.08) | 0.7            | 0.08 (–0.02, 0.2) | 0.1            | 0.02 (–0.02, 0.06) | 0.3 |
| Model 1a                        | –0.05 (–0.2, 0.05) | 0.3            | –0.06 (–0.2, 0.05) | 0.3            | 0.002 (–0.1, 0.1) | 1.0            | –0.008 (–0.05, 0.03) | 0.7 |
| Model 2b                        | –0.006 (–0.1, 0.09) | 0.9            | 0.04 (–0.06, 0.1) | 0.5            | 0.1 (0.01, 0.2) | 0.03            | 0.04 (–0.003, 0.08) | 0.07 |
| Model 3a                        | –0.008 (–0.1, 0.09) | 0.9            | 0.04 (–0.06, 0.1) | 0.4            | 0.1 (0.008, 0.2) | 0.04            | 0.04 (–0.007, 0.08) | 0.1 |

24-hour urine phosphorus, mg/day

| Unadjusted                      | 98.6 (44.2, 53.1) | <0.001 | 166.3 (112, 220.6) | 0.001 | 307.7 (253.4, 62) | <0.001 | 112.5 (93.3, 131.7) | <0.001 |
| Model 1a                        | 88.7 (36.2, 41.1) | 0.001 | 133 (79.9, 186) | 0.001 | 262.3 (206, 18.7) | <0.001 | 95.6 (75.6, 115.6) | <0.001 |
| Model 2b                        | 83.1 (30.2, 36.1) | 0.002 | 121.6 (66.4, 176.8) | 0.001 | 247.3 (187.4, 307.2) | <0.001 | 90.5 (69.1, 111.8) | <0.001 |
| Model 3a                        | 73.2 (20.4, 126) | 0.007 | 100.6 (45.1, 156) | 0.001 | 215.4 (154, 276.7) | <0.001 | 78.4 (56.3, 100.5) | <0.001 |

Fractional excretion of phosphorus, %

| Unadjusted                      | –2.3 (–3.9, –0.8) | 0.003 | –5.0 (–6.6, –3.5) | <0.001 | –5.9 (–7.4, –4.3) | <0.001 | –2.4 (–2.9, –1.8) | <0.001 |
| Model 1a                        | –1.8 (–3.3, –0.3) | 0.02 | –4.7 (–6.2, –3.1) | <0.001 | –4.9 (–6.5, –3.3) | <0.001 | –2.1 (–2.6, –1.5) | <0.001 |
| Model 2b                        | –0.8 (–2.3, 0.7) | 0.3 | –2.7 (–4.2, –1.2) | 0.001 | –2.3 (–4.0, –0.7) | 0.006 | –1.1 (–1.7, –0.5) | <0.001 |
| Model 3a                        | –0.6 (–2.1, 0.9) | 0.5 | –2.3 (–3.9, –0.8) | 0.003 | –1.7 (–3.4, 0.02) | 0.05 | –0.9 (–1.5, –0.3) | 0.006 |

Log FGF-23, RU/ml

| Unadjusted                      | –0.3 (–0.5, –0.1) | <0.001 | –0.5 (–0.6, –0.3) | <0.001 | –0.5 (–0.6, –0.3) | <0.001 | –0.2 (–0.2, –0.1) | <0.001 |
| Model 1a                        | –0.4 (–0.5, –0.2) | <0.001 | –0.5 (–0.7, –0.4) | <0.001 | –0.6 (–0.7, –0.4) | <0.001 | –0.2 (–0.3, –0.1) | <0.001 |
| Model 2b                        | –0.2 (–0.4, –0.06) | 0.006 | –0.2 (–0.4, –0.09) | 0.003 | –0.2 (–0.4, –0.02) | 0.03 | –0.05 (–0.1, 0.01) | 0.08 |
| Model 3a                        | –0.2 (–0.4, –0.08) | 0.003 | –0.02 (–0.4, –0.1) | 0.002 | –0.02 (–0.4, –0.04) | 0.02 | –0.1 (–0.1, –0.002) | 0.04 |

PTH, pg/ml

| Unadjusted                      | –6.9 (–13.1, –0.6) | 0.03 | –9.6 (–15.9, –3.4) | 0.002 | –15.4 (–21.6, –9.2) | <0.001 | –5.8 (–8.0, –3.6) | <0.001 |
| Model 1a                        | –5.2 (–11.4, 1.0) | 0.1 | –7.6 (–13.8, –1.3) | 0.02 | –11.9 (–18.6, –5.2) | <0.001 | –4.7 (–7.1, –2.4) | <0.001 |
| Model 2b                        | –0.9 (–6.9, 4.9) | 0.7 | 1.1 (–5.1, 7.3) | 0.7 | –0.4 (–7.1, 6.3) | 0.9 | –0.5 (–2.9, 1.9) | 0.7 |
| Model 3a                        | –1.6 (–7.5, 4.3) | 0.6 | 0.01 (–6.2, 6.2) | 1.0 | –2.3 (–9.1, 4.5) | 0.5 | –1.3 (–3.8, 1.2) | 0.3 |

Quartile 1 was the referent category, with the lowest urine dopamine level. * Adjusted for age, sex, and race (white, black, other). † Adjusted for age, sex, race (white, black, other), eGFRcys, and urine albumin/creatinine. ‡ Adjusted for age, sex, race, eGFRcys, urine albumin/creatinine, ACE/ARB use, heart failure, tobacco use, BMI, and diuretic use.
age, sex, and race ethnicity (p value for interactions all >0.05).

The associations of daily urine dopamine excretion with serum phosphorus, daily urine phosphorus excretion, and FGF-23 were also similar among persons with and without CKD (p value for interactions all >0.05). However, we observed that the association of 24-hour urine dopamine excretion with F Ephos was modified by CKD status. While higher urine dopamine was associated with lower F Ephos in both those with and without CKD, the association was stronger in those with eGFR <60 ml/min/1.73 m² (p value for interaction = 0.02). In adjusted models, each standard deviation higher urine dopamine was associated with a 2.8% lower F Ephos (p = 0.003) in persons with CKD and a 0.8% lower F Ephos among persons without CKD (p = 0.004). Additionally, we observed that the association of urine dopamine excretion with PTH was modified by CKD status (p value for interaction <0.001). In adjusted models, each standard deviation higher urine dopamine was associated with 13 pg/ml lower PTH in persons with CKD (p = 0.002), whereas each standard deviation higher urine dopamine was not associated with PTH in persons without CKD (p = 0.6).

Discussion

Several studies in rodents have suggested that urine dopamine may influence phosphorus homeostasis. However, to our knowledge, similar relationships have not previously been evaluated in humans. In a relatively large sample of community-living individuals with a spectrum of kidney function ranging from normal to moderate CKD, we found that higher 24-hour urine dopamine excretion was associated with higher urine phosphorus excretion; a marker of dietary phosphorus absorption. Simultaneously, higher 24-hour urine dopamine was associated with lower F Ephos. No association was observed between urine dopamine excretion and serum phosphorus concentrations, FGF-23, PTH levels, nor with serum dopamine concentrations. This suggests that greater dietary absorption of phosphorus is associated with renal generation of dopamine; however, greater dopamine is not associated with a higher F Ephos. Urine dopamine does not appear to be associated with PTH or FGF-23, suggesting that other regulatory mechanisms may be driving the association between dietary phosphorus absorption and urine dopamine production.

The direct association of urine dopamine and phosphorus excretion most likely reflects greater generation of urine dopamine in response to greater dietary phosphorus consumption. Dopamine has been well documented to affect the activity of a number of transporters in the renal proximal tubule, including Npt2a, which is a major sodium-dependent phosphate transporter in the apical membrane of the proximal tubule cells [23]. Similar to our observations in humans, studies in rodent models have demonstrated that dietary phosphorus challenge leads to endogenous production of dopamine in the proximal tubule [6–9]. In one such study in rats, a change in dietary phosphorus intake from 0.7 to 1.8% increased urinary excretion of dopamine by 23%; however, it did not change plasma dopamine levels [24]. Another study in mice found that the renal content of dopamine and the urinary excretion of dopamine was 2–3 times higher in animals on a high-phosphorus versus low-phosphorus diet [10]. Additionally, the investigators measured several enzymes involved in dopamine metabolism and found that the activity of three of the major dopamine-degrading enzymes – renalase, monoamine oxidase A, and monoamine oxidase B – were decreased in response to a high-phosphate diet [10], suggesting that the increased urine dopamine levels may reflect decreased catabolism of urine dopamine.

Despite finding that greater urine dopamine excretion was associated with higher dietary phosphorus absorption, we found that greater 24-hour urine dopamine excretion was associated with a lower F Ephos; an association that was stronger in subjects with CKD. There are several possible hypotheses to explain association of higher urine dopamine and lower F Ephos. One is that urine dopamine is associated with higher dietary phosphorus and does not induce phosphaturia. Another hypothesis is that urine dopamine may affect tubular handling of creatinine, as suggested by the strong associations between urine dopamine and urine and serum creatinine, rendering the measure of F Ephos unreliable. The negative association between urine dopamine and F Ephos is in conflict with some studies in animal models [10]. In one study, rats fed a high-phosphorus diet for several days were infused with carbidopa (an inhibitor of an enzyme important for the biosynthesis of dopamine). F Ephos decreased by 46% in the first 20 min [7]. These studies have suggested that dopamine inhibits a number of transporters in renal proximal tubule cells including Na-K-ATPase, Npt2a, and NHE3 [25, 26]. Other studies, however, are consistent with our results. One study found that inhibition of enzymes involved in urine dopamine
availability did not alter urinary excretion of dopamine or phosphorus in either 3/4 nephrectomized or sham rats, suggesting that urine dopamine does not play a significant role in the regulation of phosphorus handling by the kidney [27]. A study of rats which underwent bilateral renal denervation found that mean urinary phosphorus and urine dopamine excretion was similar compared to the rats who underwent sham surgery [9].

We did not observe an association between urine dopamine and FGF-23 or PTH. If confirmed, these findings may suggest that known mechanisms of renal tubular handling of phosphorus may not be involved in the renal dopamine-phosphorus regulatory pathway in humans. Similar findings have been suggested in animal models. For example, investigators infused inorganic phosphate into duodenal cells and found an increased urinary phosphorus excretion [28]. This phosphaturia was present even in rats who had parathyroidectomies, and measured levels of PTH and FGF-23 did not change in response to intestinal phosphate infusion [28], suggesting that additional unidentified phosphatonin or regulatory mechanisms linked to the gastro-intestinal tract may exist. Our study had several strengths. We evaluated a large, well-characterized cohort of individuals with rigorously collected timed urine collections. Few cohort studies have collected data on urine dopamine and measures of phosphorus homeostasis. The study also has important limitations. All participants had CHD, were older, were mostly male, and few had advanced CKD. Results may differ in other populations. We did not have detailed dietary histories. This was a cross-sectional study, so causal inferences and directions of association cannot be determined.

In conclusion, greater urine dopamine excretion is associated with greater urinary phosphorus excretion in patients with stable CHD. This finding suggests that endogenous renal dopamine production may be increased in response to dietary phosphorus absorption. Urine dopamine was not associated with either FGF-23 or PTH, suggesting that known mechanisms of renal tubular handling of phosphorus may not be involved in the renal dopamine-phosphorus regulatory pathway in humans. Additional studies are needed to evaluate the mechanism for these associations and the significance of urine dopamine with CKD progression and vascular disease risk.

Acknowledgements

This study was supported by grants from the American Kidney Fund (N.B.), National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK088865 to N.B. and K24 DK92291 to C.H.), National Heart Lung and Blood Institute (1R01HL096851) (J.H.I.), an American Heart Association Fellow-to-Faculty Transition Award (J.H.I.), and an award from the Sandra Daugherty Foundation (J.H.I.). The Heart and Soul Study was funded by the Department of Veterans Affairs, American Federation of Aging Research, Robert Wood Johnson Foundation, Nancy Kirwan Heart Research Fund, Ischemia Research and Education Foundation, and the NHLBI (R01 HL079235).

Disclosure Statement

None of the authors have any potential conflicts of interest. The results of this paper have not been published previously, in whole or in part, except in abstract form.

References


